Sugi Predict

Sugi Predict / Compounds / SCHEMBL8088488

SCHEMBL8088488

SCHEMBL8088488

O=C[C@@H](O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.50
▸ LMNA P02545 4/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SRC P12931 2/20 0.44
▸ CES2 O00748 2/20 0.43
▸ CES1 P23141 2/20 0.43
▸ KMT2A Q03164 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ ADRA2A P08913 1/20 0.39
▸ ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5068710 1.00 CYP2D6 (0.50) CYP2D6LMNAMAPK1KDM4EL3MBTL1
SCHEMBL1041627 1.00 CYP2D6 (0.50) CYP2D6LMNAMAPK1KDM4EL3MBTL1
SCHEMBL11703010 0.97 CYP2D6 (0.48) CYP2D6LMNAMAPK1KDM4EL3MBTL1
SCHEMBL9127753 0.97 CYP2D6 (0.48) CYP2D6LMNAMAPK1KDM4EL3MBTL1
SCHEMBL8591948 0.86 ACP3 (0.48) CYP2D6LMNAALDH1A1
SCHEMBL8591731 0.81 SRD5A2 (0.54) TSHR
SCHEMBL9656453 0.78 LMNA (0.46) CYP2D6LMNAMAPK1KDM4EL3MBTL1
SCHEMBL9656438 0.78 LMNA (0.46) CYP2D6LMNAMAPK1KDM4EL3MBTL1
SCHEMBL15018764 0.77 ESR1 (0.44) CYP2D6LMNAKDM4ESRCKMT2A
SCHEMBL11879383 0.76 LMNA (0.44) CYP2D6LMNAMAPK1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 — — EP disclosed
CN-118510768-A Diazasulfinyl structure-containing compounds and their use in medicine 赛诺哈勃药业（成都）有限公司 2024-08-16 — — CN disclosed
EP-3558980-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2019-10-30 — — EP disclosed
WO-2018115275-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION IRBM SCIENCE PARK S.P.A. (IT) 2018-06-28 — — WO disclosed
US-20170067084-A1 PRODUCTION OF CHIRAL 1,2-AMINO ALCOHOLS AND ALPHA-AMINO ACIDS FROM ALKENES BY CASCADE BIOCATALYSIS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2017-03-09 — — US disclosed
US-20170067084-A1 PRODUCTION OF CHIRAL 1,2-AMINO ALCOHOLS AND ALPHA-AMINO ACIDS FROM ALKENES BY CASCADE BIOCATALYSIS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2017-03-09 — — US disclosed
US-20170067084-A1 PRODUCTION OF CHIRAL 1,2-AMINO ALCOHOLS AND ALPHA-AMINO ACIDS FROM ALKENES BY CASCADE BIOCATALYSIS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2017-03-09 — — US disclosed
EP-2885294-B1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES INC (US) 2016-11-30 — — EP disclosed
US-9409891-B2 Solid forms of an antiviral compound GILEAD PHARMASSET LLC (US) 2016-08-09 — — US disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 — — US disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 — — US disclosed
US-9045462-B2 Synthesis of an antiviral compound GILEAD SCIENCES, INC. (US) 2015-06-02 — — US disclosed
US-20140309187-A1 SOLID FORMS OF AN ANTIVIRAL COMPOUND GILEAD PHARMASSET LLC 2014-10-16 — — US disclosed
US-8841340-B2 Solid forms of an antiviral compound GILEAD SCIENCES, INC. (US) 2014-09-23 — — US disclosed
US-20140275570-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2014-09-18 — — US disclosed
US-20140051749-A1 SOLID FORMS OF AN ANTIVIRAL COMPOUND GILEAD PHARMASSET LLC 2014-02-20 — — US disclosed
WO-2014028342-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2014-02-20 — — WO disclosed
US-8299255-B2 3,8-diaminotetrahydroquinoline derivative ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-10-30 — — US disclosed
US-20100317693-A1 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE ZERIA PHARMACEUTICAL CO., LTD (JP) 2010-12-16 — — US disclosed
WO-2009039362-A2 CHIRAL SYNTHESIS OF DIAZEPINOQUINOLINES WYETH (US) 2009-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275570-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND EIF2AK2, SARS1, MAVS CYP2D6 572/4885LMNA 4014/4885MAPK1 1915/4885
US-20140051749-A1 SOLID FORMS OF AN ANTIVIRAL COMPOUND EIF2AK2, ZC3HAV1, ZC3HAV1L CYP2D6 944/4885LMNA 2574/4885MAPK1 3065/4885
US-20140309187-A1 SOLID FORMS OF AN ANTIVIRAL COMPOUND EIF2AK2, ZC3HAV1, ZC3HAV1L CYP2D6 944/4885LMNA 2574/4885MAPK1 3065/4885
US-20100317693-A1 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE GHSR, GHRHR, GNRHR CYP2D6 2915/4885LMNA 1843/4885MAPK1 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.